CuraSen Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• CST-3056 · Oncology
  CST-3056 is a small molecule inhibitor of the CDK9 enzyme.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CuraSen Therapeutics, Inc. portfolio CI brief
• CuraSen Therapeutics, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies